08158.HK
China Regenerative Medicine International Limited
HKSE · Healthcare · Biotechnology · HK
HKD 0.25
−0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 107.3M | 72.1M | 90.6M | 69.5M | 41.5M |
| Cost of Revenue | 46.8M | 30.1M | 33.0M | 50.1M | 3.9M |
| Gross Profit | 60.5M | 41.9M | 57.7M | 19.4M | 37.6M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 49.7M | 42.4M | 51.5M | 45.5M | 25.8M |
| General & Admin Expense | 30.3M | 36.8M | 44.9M | 38.9M | 22.2M |
| Selling & Marketing Expense | 4.6M | 5.5M | 6.6M | 6.6M | 3.6M |
| Other Expenses | 1.2M | 1.2M | (12.7M) | 83.0M | — |
| Total Operating Expenses | 50.9M | 43.5M | 38.8M | 128.5M | 25.8M |
| Cost and Expenses | 82.7M | 73.6M | 71.7M | 178.6M | 29.2M |
| Operating Income (EBIT) | 45.6M | 16.4M | 18.9M | (109.1M) | 12.3M |
| Non-Operating | |||||
| Interest Income | 10.5M | 18.0M | 17.6M | 12.0K | 1.0K |
| Interest Expense | 1.6M | 1.2M | 1.1M | 979.0K | 781.0K |
| Net Interest Income | 12.4M | 16.8M | 16.4M | (967.0K) | (780.0K) |
| Other Non-Op Income/Expense | (28.1M) | (1.2M) | (1.1M) | 1.4M | (4.0M) |
| Non-Operating Income (excl Interest) | 6.9M | 16.8M | (458.0K) | (2.4M) | — |
| EBT (Pre-Tax Income) | 17.5M | 15.2M | 17.8M | (107.7M) | 8.3M |
| Income Tax Expense | (6.2M) | 12.3M | — | — | 3.7M |
| Bottom Line | |||||
| Net Income | 29.9M | 27.5M | 17.8M | (107.7M) | 4.6M |
| Earnings from Cont. Ops | 41.3M | 27.5M | 17.8M | (107.7M) | 4.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 29.9M | 27.5M | 17.8M | (107.7M) | 4.6M |
| Per Share | |||||
| Basic EPS | HK$0.10 | HK$0.09 | HK$0.06 | (HK$0.38) | HK$0.02 |
| Diluted EPS | HK$0.10 | HK$0.09 | HK$0.06 | (HK$0.38) | HK$0.02 |
| Revenue Per Share | HK$0.35 | HK$0.24 | HK$0.30 | HK$0.24 | HK$0.15 |
| Shares | |||||
| Basic Shares Outstanding | 304.3M | 304.3M | 304.3M | 286.4M | 285.4M |
| Diluted Shares Outstanding | 304.3M | 304.3M | 304.3M | 286.4M | 285.4M |
| Profitability Metrics | |||||
| EBITDA | 24.9M | 8.3M | 29.8M | (95.4M) | 9.9M |
| D&A | 15.3M | 9.9M | 11.0M | 11.3M | 5.4M |
| EBIT | 9.7M | (1.6M) | 18.9M | (106.7M) | 4.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026